Lantern Pharma Secures EU Patent for AI-Designed Cancer Drug LP-284
Lantern Pharma's EU patent for LP-284, an AI-designed cancer drug, marks a significant step in global commercialization and treatment for non-Hodgkin’s lymphoma.
Lantern Pharma (NASDAQ: LTRN) has achieved a significant milestone with the European Patent Office issuing a notice of allowance for a composition of matter patent for LP-284, its clinical-stage drug candidate aimed at treating relapsed or refractory non-Hodgkin’s lymphoma. This patent, which is expected to grant exclusivity through 2039, complements existing intellectual property protections in the U.S. and Japan, facilitating the global commercialization of LP-284.
Developed using Lantern’s innovative RADR(R) AI platform, LP-284 is currently in Phase 1 clinical trials and has been granted Orphan Drug Designations for mantle cell lymphoma (MCL) and high-grade B-cell lymphoma (HGBL). The drug is targeting a substantial global market estimated at $4 billion. The rapid development timeline and cost efficiency of LP-284, underscored by its advancement from initial AI insights to first-in-human clinical trials in just 2-3 years at approximately $2.5 million per program, enhance Lantern Pharma's potential for strategic partnerships.
For more details on this development, visit https://ibn.fm/Rx6Jq.